Cart
sales@molnova.com
Home - Products - Endocrinology/Hormones - Reductase - PHA767491 HCl

PHA767491 HCl

CAS No. 942425-68-5

PHA767491 HCl( CAY-10572 hydrochloride )

Catalog No. M19277 CAS No. 942425-68-5

PHA-767491 is an effective ATP-competitive dual Cdc7/CDK9 inhibitor (IC50: 10/34 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 46 In Stock
5MG 41 In Stock
10MG 58 In Stock
25MG 93 In Stock
50MG 133 In Stock
100MG 219 In Stock
200MG 324 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    PHA767491 HCl
  • Note
    Research use only, not for human use.
  • Brief Description
    PHA-767491 is an effective ATP-competitive dual Cdc7/CDK9 inhibitor (IC50: 10/34 nM).
  • Description
    PHA-767491 is an effective ATP-competitive dual Cdc7/CDK9 inhibitor (IC50: 10/34 nM). It has ~20-fold selectivity against GSK3-β and CDK1/2, 50-fold selectivity against CDK5 and MK2, 100-fold selectivity against CHK2 and PLK1.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    CAY-10572 hydrochloride
  • Pathway
    Endocrinology/Hormones
  • Target
    Reductase
  • Recptor
    Cdk1| Cdk2| Cdk9| Cdc7| GSK-3β
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    942425-68-5
  • Formula Weight
    213.24
  • Molecular Formula
    C12H11N3O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 17.33 mg/mL 69.40 mM
  • SMILES
    Cl.O=C1NCCc2nc(cc12)c3ccncc3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Montagnoli A, et al. Nat Chem Biol, 2008, 4(6), 357-365.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • BYAKANGELICIN(b)

    BYAKANGELICINa main furanocoumarin constituent isolated and characterized as an aldose reductase inhibitorand is effective for the treatment of sugar cataracts and diabetic neuropathy and hence might be useful as a lead compound for the development of new type drugs for clinical use.

  • Ponalrestat

    ponalrestat, an aldose reductase inhibitor, activates lipoprotein lipase (LPL) activity in the adipose tissue and alleviates the cachectic symptoms induced by B16 melanoma in mice

  • Ganoderic acid C2

    Ganoderic acid C2 has anti-inflammatory,and anti-tumor-promoting activities. Ganoderic acid C2 can inhibit histamine release, it also has inhibitory effects on the induction of Epstein-Barr Virus early antigen.

Sign In Join Free